Gadoxetic acid-based hepatobiliary MRI in hepatocellular carcinoma.

ABSTRACT:

Background & aims

SORAMIC is a prospective phase II randomised controlled trial in hepatocellular carcinoma (HCC). It consists of 3 parts: a diagnostic study and 2 therapeutic studies with either curative ablation or palliative Yttrium-90 radioembolisation combined with sorafenib. We report the diagnostic cohort study aimed to determine the accuracy of gadoxetic acid-enhanced magnetic resonance imaging (MRI), including hepatobiliary phase (HBP) imaging features compared with contrast-enhanced computed tomography (CT). The primary objective was the accuracy of treatment decisions stratifying patients for curative or palliative (non-ablation) treatment.

Methods

Patients with clinically suspected HCC underwent gadoxetic acid-enhanced MRI (HBP MRI, including dynamic MRI) and con

SUBMITTER: Ricke J 

PROVIDER: S-EPMC7578758 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature